Abstract: A composition for a medical device is described. The composition comprises a specific mucoadherent gelling complex composed of EPS, exopolysaccharides of bacterial origin produced in situ in the gastrointestinal tract by specific selected bacterial strains, in association with vegetable gums and/or animal and/or vegetable gelatines. The complex is capable of establishing a complete barrier effect of a mechanical type extending throughout the whole gastrointestinal tract and can be used as a medication for the prevention and treatment of all pathologies connected to a deficiency in the barrier effect in the gastrointestinal area due to a low production of mucus, such as, by way of non-exhaustive example, intestinal permeability and bacterial translocation.

Abstract: Tyndallized, intact and immunologically active bacterial cells of Lactobacillus rhamnosus GG (ATCC 53103) is described. A method for preparing the same, as well as an analytical method for the qualitative and quantitative determination of tyndallized, intact and immunologically active bacterial cells of Lactobacillus rhamnosus GG (ATCC 53103) is also described.

Abstract: Use of rutin for increasing the effectiveness of chemotherapeutic treatments used in human and veterinary medicine for the treatment of tumors is described, in particular in case of resistance to chemotherapeutics currently in use.

Abstract: The present invention relates to a fully moisture-tight multilayer material, which is also able to absorb, retain and not release the absorbed moisture or free water into the formulations containing pharmacological active substances and/or instable components with biological activity and/or effervescent and/or easily perishable formulations; said material being useful for preparing bags, envelopes and sachets for packaging food, dietary and cosmetic products, medical devices and medicinal products. The multilayer material of the present invention is a multilayer material that is useful for preparing containers in the form of bags, envelopes, sachets and sticks coming into direct contact with the formulations of the food, dietary and cosmetic products as well as of the medical devices and medicinal products in the form of e.g. lactic bacteria and/or bifidobacteria in powders or granules, either dried or freeze-dried.

Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.

Abstract: The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

Abstract: A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis.

Abstract: The present invention relates to a composition comprising two probiotic strains of bacteria capable of performing an antioxidant and/or antibacterial and competitive action against species of coliform bacteria that produce gas by fermentation of sugar, in particular lactose, isolated from infants affected by colic.

Abstract: The object of the present invention is a probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the contemporaneous improvement of the intestinal functionality, which can be compromised by therapeutic treatments adopted for re-solving said pathological conditions. Besides that, aim of this invention is a probiotic bacteria-based composition comprising moreover a suitable quantity of at least a substance or nourishment having prebiotic properties and eventually, of suitable pharmacologically active substances.

Abstract: The present invention relates to a selected strain of Lactobacillus pentosus for use as a medication for the preventive or curative treatment of infections due to Gram-negative bacteria, preferably enterococci, coliforms and E. coli.

Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.

Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.

Abstract: The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

Abstract: The present invention relates to a composition comprising two probiotic strains of bacteria capable of performing an antioxidant and/or antibacterial and competitive action against species of coliform bacteria that produce gas by fermentation of sugar, in particular lactose, isolated from infants affected by colic.

Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.

Abstract: The present invention relates to a selected strain of Lactobacillus pentosus for use as a medication for the preventive or curative treatment of infections due to Gram-negative bacteria, preferably enterococci, coliforms and E. coli.

Abstract: The present invention relates to folic acid-producing bacterial strains belonging to the genus Bifidobacterium, pharmaceutical, veterinary or food formulations containing them and the use thereof. In particular, the invention relates to new bacterial strains of human origin belonging to the genus Bifidobacterium, adolescentis species (2), the genus Bifidobacterium, breve species (1) and the genus Bifidobacterium, pseudocatenulatum species (2) deposited in the DSMZ collection center (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; Braunsweig, Germany), in accordance with the Treaty of Budapest, on 21 Jul. 2004.

Abstract: The present invention relates to probiotic bacteria strains having a high anti-inflammatory activity. The present invention relates to bacteria strains as strongly inducers of Interleukin-10 (IL-10) production. In particular, the present invention relates to the anti-inflammatory activity shown by said bacteria strains due to its enhancement of IL-10 production in peripheral blood mononuclear cells, with on the other hand a low capability to stimulate the production of the pro-inflammatory 11-12, thus leading to a high IL-10/IL-12 ratio. Further, the present invention relates to the use of at least one bacterium strain for the preparation of a composition for the prevention or treatment of the inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS). Finally, the present invention relates to food products, such as probiotic dietary supplements containing at least one probiotic bacterium strain, as an active ingredient.

Abstract: The present invention refers to an oily suspension containing probiotic bacteria, particularly suitable for paediatric use.

Abstract: The present invention refers to a food product. In particular, the present invention refers to a form of administration of a high and stable load of probiotic bacteria preferentially to persons of paediatric age. The present invention furthermore refers to a chocolate flavoured probiotic supplement, in particular to a probiotic tablet comprising an inner part, represented by a core of chocolate containing coated probiotic bacteria, and an outer part, represented by an outer coating. In particular, the present invention refers to a form of administration of a high and stable load of probiotic bacteria.